Rossignol Medical Center

This Phase 2 study tests whether TB006, an antibody that targets a protein called Galectin-3, can improve core symptoms of autism in adults aged 18 to 35. Forty-five participants will be randomly assigned to receive either TB006 or a placebo for 14 weeks, with an open-label exten…